EUVIMEDEUVIMED entdecken
Crossref

EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER

Ronac Mamtani, Monika Raut, Hal Yapici, Weiqi Jiao, Frank Su, Annabelle Davies, Joyce Y. Lai, Haojie Li, Nancy Davis

Value in Health · 2026-06 · 29 (6) · S73-S74

DOI: 10.1016/j.jval.2026.03.353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Ronac Mamtani und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Mamtani, R., Raut, M., Yapici, H., Jiao, W., Su, F., Davies, A., Lai, J. Y., Li, H., & Davis, N. (2026). EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER. Value in Health, 29(6), S73-S74. https://doi.org/10.1016/j.jval.2026.03.353

Vancouver

Mamtani R, Raut M, Yapici H, Jiao W, Su F, Davies A, et al. EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER. Value in Health. 2026;29(6):S73-S74. doi:10.1016/j.jval.2026.03.353

BibTeX
@article{Mamtani2026,
  author = {Mamtani, Ronac and Raut, Monika and Yapici, Hal and Jiao, Weiqi and Su, Frank and Davies, Annabelle and Lai, Joyce Y. and Li, Haojie and Davis, Nancy},
  title = {EE58 ECONOMIC BURDEN OF RECURRENCE AFTER TRIMODAL THERAPY FOR BLADDER CANCER},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S73--S74},
  doi = {10.1016/j.jval.2026.03.353}
}
Kostenlos starten →